Literature DB >> 6727138

Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure.

R J McGonigle, F Husserl, J D Wallin, J W Fisher.   

Abstract

Parameters of erythropoiesis were studied in patients with endstage renal disease established on continuous ambulatory peritoneal dialysis (CAPD) and regular hemodialysis treatment (RDT). Serum erythropoietin was measured by radioimmunoassay, and erythroid progenitor cell (CFU-E) formation was assayed in fetal mouse liver cultures. Serum erythropoietin concentrations in both CAPD (35.3 +/- 4.0 mU/ml) and RDT (31.9 +/- 1.9 mU/ml) patients were significantly higher (P less than 0.01) than normal values (23.1 +/- 1.0 mU/ml). The serum erythropoietin concentration did not correlate with either hematocrit or inhibition of CFU-E formation in either group of dialysis patients. In both CAPD and RDT patients the hematocrit correlated significantly (P less than 0.001) with the degree of serum inhibition of CFU-E formation. CFU-E formation decreased from 74.5 +/- 2.5 to 62.5 +/- 3.5% of control with increasing concentrations of uremic serum in cell cultures from 5 to 20%. In RDT patients a single hemodialysis produced a decrease in the mean serum erythropoietin concentration from 31.8 +/- 2.1 to 27.4 +/- 1.8 mU/ml (P less than 0.01) but no significant change in CFU-E formation. In conclusion, although serum immunoreactive erythropoietin levels are elevated above the normal range in dialysis patients, the response remains inadequate for the severity of the anemia, and it is the degree of serum inhibition of erythropoiesis in both CAPD and RDT patients which correlates with and possibly determines the degree of anemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727138     DOI: 10.1038/ki.1984.35

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 2.  Erythropoietin: an old friend revisited.

Authors:  H Hambley; G J Mufti
Journal:  BMJ       Date:  1990-03-10

3.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

Review 4.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 5.  The use of erythropoietin in renal failure.

Authors:  I C Macdougall; R D Hutton; G A Coles; J D Williams
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

6.  Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure.

Authors:  N Cakar; M Ekim; N Tümer; F Yalçinkaya; N Akar; H O Onaran
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

7.  Improved microbioassay for plasma erythropoietin based on CFU-E colony formation.

Authors:  S Sakata; Y Enoki
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

Review 8.  Erythropoiesis and erythropoietin levels in renal transplant recipients.

Authors:  M Wolff; W Jelkmann
Journal:  Klin Wochenschr       Date:  1991-01-22

9.  Effect of different modes of dialysis on serum erythropoietin levels in pediatric patients. A report of the Southwest Pediatric Nephrology Study Group.

Authors:  B S Beckman; J W Brookins; R K Shadduck; K F Mangan; L J Deftos; J W Fisher
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

10.  End-stage kidneys are capable of increased erythropoietin production.

Authors:  K Morris; M Coulthard
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.